PRAME (PReferentially expressed Antigen in MElanoma) is a tumor biomarker expressed in most cutaneous and ocular melanomas as well as various other malignant neoplasms.1
PRAME expression in formalin-fixed paraffin-embedded tissue is detected by immunohistochemistry and frequently demonstrates a diffuse nuclear immunostaining pattern in in situ and invasive melanoma. In contrast, the majority of benign melanocytic nevi lack nuclear PRAME staining.2
Studies suggest that detection of PRAME expression by immunohistochemistry (IHC) may complement findings from routinely used H&E and other IHC panels and aid in:
References